Last reviewed · How we verify
NCT03769220: 5iTUG
Evaluation of the Measurement Properties of a 5 Time Repeated Instrumented Timed Up and Go (5iTUG)
trial in Measurement Properties of 5iTUG in 60 participants. Completed in 16 September 2019.
16 September 2019
Quick facts
| Lead sponsor | Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF) |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 10 December 2018 |
| Primary completion | 16 September 2019 |
| Estimated completion | 16 September 2019 |
| Sites | 1 location across Germany |
Conditions studied
- Measurement Properties of 5iTUG — all drugs for Measurement Properties of 5iTUG →
- Physical Disability — all drugs for Physical Disability →
- Balance — all drugs for Balance →
- Cognitive Impairment — all drugs for Cognitive Impairment →
Sponsor
Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF) — full company profile →
Who can join
Adults 60 to 80, any sex, with Measurement Properties of 5iTUG or Physical Disability. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In order to tailor interventions, objective assessments of physical function is needed. A limitation of several of today's clinical assessments is that they require too much time and/or space. The Timed Up and Go (TUG) is a commonly used clinical test of physical function in older populations. The TUG is particularly useful due to its short administration time and the little space that is required. The TUG is however of limited value when used in higher-functioning older adults due to ceiling effects. Instrumented versions of TUG (iTUG) computes several outcome measures in addition to the traditional outcome measure which is the total duration. The aim of this study is to evaluate the construct- and discriminative validity of outcomes derived from sensor signals recorded with a smartphone during a five times repeated iTUG (5iTUG).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03769220
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF) trials
Trials by the same sponsor.
- NCT07423039 — Auricular Acupressure for Perioperative Anxiety and Pain in Therapeutic Breast Surgery (ROSA) · NA · not yet recruiting
- NCT06931132 — Cancer-related Fatigue and Symptom Clusters - Effects of Virtual, Imagined and Real-life Nature-based Therapy in Cancer · NA · enrolling by invitation
- NCT03931928 — Genotype and Phenotype Guided Supplementation of TAMoxifen Standard Therapy With ENDOXifen in Breast Cancer Patients · Phase 2 · completed
- NCT03100201 — Robotic-assisted Training After Upper Arm Fracture · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03769220 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)
- Last refreshed: 26 September 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03769220.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing